A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)
Trial details
- Registry ID
- NCT04592419
- Phase
- Phase 3
The FDA approved Aflibercept (Eylea) on 18 Nov 2011.
Drug identity checked against registry records
Also recorded as Eylea
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2011-11-18Day | Aflibercept | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "BLA125387", "applicant_as_listed_by_fda": "REGENERON PHARMACEUTICALS", "brand_names": ["EYLEA"], "active_ingredients": ["AFLIBERCEPT"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20111118", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |